Genome-wide study of response to platinum, taxane, and combination therapy in ovarian cancer: in vitro phenotypes, inherited variation, and disease recurrence
Abstract:Background: The standard treatment for epithelial ovarian cancer (EOC) patients with advanced disease is carboplatin-paclitaxel combination therapy following initial debulking surgery, yet there is wide inter-patient variation in clinical response. We sought to identify pharmacogenomic mar...
Main Authors: | Brooke L Fridley, Taraswi Mitra Ghosh, Alice eWang, Rama eRaghavan, Junqiang eDai, Ellen L Goode, Jatinder K Lamba |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-03-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fgene.2016.00037/full |
Similar Items
-
Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review
by: Shuji Ota, et al.
Published: (2019-01-01) -
Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-07-01) -
Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-09-01) -
Factors Affecting Mortality of Sepsis Patients in General Hospital Dr. M. Djamil Padang
by: Kornelis Aribowo, et al.
Published: (2024-08-01) -
Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
by: Yanxiu Guo, et al.
Published: (2018-01-01)